GLP-1 Medication Eligibility: Who Qualifies for Semaglutide and Tirzepatide?

The FDA has established specific criteria for prescribing GLP-1 medications for weight management. For Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), the approved indications require a BMI of 30 or greater (obesity) in adults, or a BMI of 27 or greater (overweight) in adults who also have at least one weight-related comorbidity.

Qualifying weight-related comorbidities include type 2 diabetes, high blood pressure (hypertension), high cholesterol (dyslipidemia), obstructive sleep apnea, and cardiovascular disease. Some clinicians also consider conditions like polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease, and osteoarthritis when evaluating eligibility.

For the diabetes indications (Ozempic and Mounjaro), the primary criterion is a diagnosis of type 2 diabetes, regardless of BMI. These medications are prescribed alongside diet and exercise to improve glycemic control. Many patients with type 2 diabetes experience significant weight loss as an additional benefit of treatment.

To determine your BMI, divide your weight in pounds by your height in inches squared, then multiply by 703. For example, if you weigh 200 pounds and are 5'6" (66 inches), your BMI is (200 / 66^2) x 703 = 32.3, which would qualify you for GLP-1 treatment.

Here are some reference points for common heights. At 5'4", a BMI of 30 corresponds to approximately 175 pounds. At 5'7", the threshold is about 192 pounds. At 5'10", it's approximately 209 pounds. At 6'0", a BMI of 30 corresponds to roughly 221 pounds. If your BMI is between 27 and 30, you would need a qualifying comorbidity to be eligible.

It's important to note that clinicians use clinical judgment alongside BMI. If your BMI is slightly below 30 but you have significant metabolic risk factors, or if you have previously had a higher BMI and lost weight through other means, your provider may still consider GLP-1 treatment appropriate. Conversely, not everyone with a qualifying BMI is automatically a candidate — other factors like medical history and contraindications must be evaluated.

Several medical conditions can influence whether GLP-1 medications are appropriate for you. Contraindications — conditions that rule out treatment — include a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), known hypersensitivity to semaglutide or tirzepatide, and pregnancy or breastfeeding.

Conditions requiring careful evaluation and monitoring include a history of pancreatitis, severe gastrointestinal disease (such as gastroparesis or inflammatory bowel disease), severe kidney disease, diabetic retinopathy, and a history of eating disorders. Patients with these conditions may still be candidates, but treatment requires close medical supervision and may involve more gradual dosing.

Some medical conditions actually strengthen the case for GLP-1 treatment. Patients with type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, PCOS, or obstructive sleep apnea may benefit from GLP-1 medications beyond weight loss alone, as these medications address multiple aspects of metabolic health simultaneously.

GLP-1 medications for weight management are currently FDA-approved for adults aged 18 and older. Wegovy recently received approval for adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex, though this is typically managed by pediatric specialists. Patients under 18 should be evaluated by a provider experienced in pediatric obesity management.

There is no strict upper age limit for GLP-1 treatment, but older adults (65+) require additional considerations. Older patients may be more susceptible to dehydration from GI side effects, may have higher risk of muscle loss during weight loss, and are more likely to take multiple medications that could interact with GLP-1 therapy. Dose escalation may be more gradual, and protein intake and strength training become even more important.

GLP-1 medications are prescribed to patients of all genders and ethnicities. However, clinicians may consider that BMI cutoffs may not be equally appropriate across all ethnic groups. For example, individuals of South Asian or East Asian descent may face elevated metabolic risk at lower BMI levels, and some guidelines recommend lower BMI thresholds for these populations.

At Weight Method, the eligibility process begins with our online health assessment quiz. The quiz collects your height, weight, age, health conditions, and medical history to determine preliminary eligibility. The entire process takes about three to five minutes and is completely free.

Our eligibility criteria at Weight Method align with FDA guidelines. You may qualify if your BMI is 30 or greater, or if your BMI is 27 or greater and you have a qualifying health condition like diabetes, high blood pressure, or high cholesterol. You must be at least 18 years old and not have any contraindications to GLP-1 therapy.

After the quiz, eligible patients are connected with a licensed clinician who reviews their health profile and discusses treatment options. The clinician determines whether semaglutide ($297/month) or tirzepatide ($349/month) is the better fit based on your individual health needs and goals. If approved, medication is shipped directly to your door, and you receive ongoing medical support throughout your treatment journey.